Biotronik said yesterday that it began enrolling patients in a trial designed to assess the safety and efficacy of a new coronary drug-eluting stent in de novo coronary artery lesions.
The Biovitesse polymer-free device combines ultra-thin struts with a new anti-proliferative limus drug designed to stop excessive cell growth, the company reported.
Get the full story at our sister site, Drug Delivery Business News.
The post Biotronik launches trial to test new coronary drug-eluting stent appeared first on MassDevice.
from MassDevice http://ift.tt/2yWemaq
Cap comentari:
Publica un comentari a l'entrada